English  |  正體中文  |  简体中文  |  Items with full text/Total items : 18368/20624 (89%)
Visitors : 16430365      Online Users : 169
RC Version 7.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
  • Adv. Search
    HomeLoginUploadHelpAboutAdminister Goto mobile version
    Please use this identifier to cite or link to this item: https://ir.cnu.edu.tw/handle/310902800/32183

    標題: Preprogramming therapeutic response of PI3K/mTOR dual inhibitor via the regulation of EHMT2 and p27 in pancreatic cancer
    作者: Tian, Yu-Feng
    Wang, Hui-Ching
    Luo, Chi-Wen
    Hung, Wen-Chun
    Lin, Yu-Han
    Chen, Tzu-Yi
    Li, Chien-Feng
    Lin, Chen-Yi
    Pan, Mei-Ren
    貢獻者: Chi Mei Med Ctr, Dept Surg, Div Colorectal Surg
    Chia Nan Univ Pharm & Sci, Dept Hlth & Nutr
    Kaohsiung Med Univ, Coll Med, Grad Inst Clin Med
    Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Dept Internal Med, Div Hematol & Oncol
    Chang Gung Mem Hosp, Kaohsiung Med Ctr, Div Cardiol
    Natl Hlth Res Inst, Natl Inst Canc Res
    Chi Mei Med Ctr, Dept Pathol
    Natl Hlth Res Inst, Natl Inst Canc Res
    Southern Taiwan Univ Sci & Technol, Dept Biotechnol
    Chi Mei Med Ctr, Dept Internal Med, Div Gastroenterol & Hepatol
    關鍵字: EHMT2
    pancreatic cancer
    cell cycle
    日期: 2018
    上傳時間: 2019-11-15 15:44:06 (UTC+8)
    摘要: Pancreatic ductal adenocarcinoma (PDAC) is an aggressive disease, which is characterized by its high invasiveness, rapid progression, and profound resistance to therapy. Gemcitabine is the first-line treatment option for pancreatic cancer patients, but the overall survival is quite low. Therefore, it is an urgent issue to identify new molecules for improved therapies, with better efficacy and less toxicity. Our previous data indicated that Euchromatic histone-lysine N-methyltransferase 2 (EHMT2) functions as a therapeutic target to override GEM resistance and promote metastasis in the treatment of pancreatic cancer. Here, we screened a small-molecule library of 143 protein kinase inhibitors, to verify cytotoxicity of different inhibitors in EHMT2-depleted cells. We determined that the EHMT2 plays a promising modulating role for targeted PI3K/mTOR inhibition. Our data revealed that EHMT2 down-regulates p27 expression, and this contributes to tumor growth. The depletion of EHMT2, ectopic expression of methyltransferase-dead EHMT2, or treatment with an EHMT2 inhibitor decreases H3K9 methylation of p27 promoter and induces G1 arrest in PANC-1 pancreatic cancer cells. Consistent with these findings, in vivo tumor xenograft models, primary tumors, and the Oncomine database utilizing bioinformatics approaches, also show a negative correlation between EHMT2 and p27. We further demonstrated that low EHMT2 elevated BEZ235 sensitivity through up-regulation of p27 in PDAC cells; high levels of SKP2 decrease BEZ235 responsiveness in PDAC cells. Altogether, our results suggest the EHMT2-p27 axis as a potential marker to modulate cell response to dual PI3K/mTOR inhibition, which might provide a strategy in personalized therapeutics for PDAC patients.
    關聯: Minerva Anestesiologica, v.8, n.9, pp.1812-1822
    Appears in Collections:[保健營養系(所) ] 期刊論文

    Files in This Item:

    File Description SizeFormat
    ajcr0008-1812.pdf1642KbAdobe PDF126View/Open

    All items in CNU IR are protected by copyright, with all rights reserved.

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback